Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


27.05.2024

1 BJU Int
1 BMC Cancer
1 BMC Urol
2 Eur Radiol
6 Eur Urol
1 Int J Urol
3 J Nucl Med
1 J Urol
2 Oncogene
1 Oncology (Williston Park)
1 Pol J Radiol
1 Radiol Imaging Cancer
1 Radiology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BJU Int

  1. GALIETTA E, Strolin S, Lodi-Rizzini E, Castellucci P, et al
    Case of the month from the Radiotherapy Unit, Department of Medical and Surgical Sciences, University of Bologna, Italy: breaking boundaries beyond five lesions with multifocal stereotactic radiotherapy in prostate cancer.
    BJU Int. 2024 May 22. doi: 10.1111/bju.16399.
    PubMed        


    BMC Cancer

  2. CUI F, Tang X, Man C, Fan Y, et al
    Prognostic value of 17-Gene genomic prostate score in patients with clinically localized prostate cancer: a meta-analysis.
    BMC Cancer. 2024;24:628.
    PubMed         Abstract available


    BMC Urol

  3. OGATA Y, Akatsuka J, Endo Y, Mikami H, et al
    Index tumor location affected early biochemical recurrence after radical prostatectomy in patients with negative surgical margin: a retrospective study.
    BMC Urol. 2024;24:108.
    PubMed         Abstract available


    Eur Radiol

  4. BREMBILLA G, Giganti F
    Improving image quality in prostate MRI: the time is now.
    Eur Radiol. 2024;34:3385-3386.
    PubMed        

  5. OERTHER B, Engel H, Nedelcu A, Strecker R, et al
    Performance of an ultra-fast deep-learning accelerated MRI screening protocol for prostate cancer compared to a standard multiparametric protocol.
    Eur Radiol. 2024 May 23. doi: 10.1007/s00330-024-10776.
    PubMed         Abstract available


    Eur Urol

  6. VYNCKIER P, Annemans L, Raes S, Amrouch C, et al
    Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe.
    Eur Urol. 2024 May 23:S0302-2838(24)02378-9. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  7. WEINER AB, Kakani P, Armstrong AJ, Bossi A, et al
    Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review.
    Eur Urol. 2024 May 22:S0302-2838(24)02375-3. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  8. RAVI P, Xie W, Buyse M, Halabi S, et al
    Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials.
    Eur Urol. 2024 May 21:S0302-2838(24)02380-7. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  9. DALLA VOLTA A, Valcamonico F, Zivi A, Procopio G, et al
    Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide.
    Eur Urol. 2024 May 20:S0302-2838(24)02347-9. doi: 10.1016/j.eururo.2024.
    PubMed        

  10. JOSEFSSON A, Mansson M, Kohestani K, Spyratou V, et al
    Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GOTEBORG-2 Prostate Cancer Screening Trial.
    Eur Urol. 2024 May 20:S0302-2838(24)02379-0. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  11. BROOKMAN-MAY SD, Buyse M, Freedland SJ, Miladinovic B, et al
    Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer.
    Eur Urol. 2024 May 17:S0302-2838(24)02348-0. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available


    Int J Urol

  12. WATANABE H, Nakane K, Takahara K, Naiki T, et al
    Prognostic outcomes in Japanese patients with metastatic castration-sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor.
    Int J Urol. 2024 May 19. doi: 10.1111/iju.15498.
    PubMed         Abstract available


    J Nucl Med

  13. FLEMING MT, Hermsen R, Purysko AS, Chau A, et al
    True-Positive (18)F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study.
    J Nucl Med. 2024 May 23:jnumed.123.267271. doi: 10.2967/jnumed.123.267271.
    PubMed         Abstract available

  14. IMBERTI C, De Gregorio R, Korsen JA, Hoang TT, et al
    CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
    J Nucl Med. 2024 May 23:jnumed.123.267107. doi: 10.2967/jnumed.123.267107.
    PubMed         Abstract available

  15. PANDIT-TASKAR N, O'Donoghue JA, Chetty D, Max S, et al
    A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 May 23:jnumed.124.267416. doi: 10.2967/jnumed.124.267416.
    PubMed         Abstract available


    J Urol

  16. BAHLER CD, Tachibana I, Tann M, Collins K, et al
    Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial.
    J Urol. 2024 May 24:101097JU0000000000004032. doi: 10.1097/JU.0000000000004032.
    PubMed         Abstract available


    Oncogene

  17. ZHAO J, Shen J, Mao L, Yang T, et al
    Cancer associated fibroblast secreted miR-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer.
    Oncogene. 2024 May 20. doi: 10.1038/s41388-024-03057.
    PubMed         Abstract available

  18. TAHSIN S, Sane NS, Cernyar B, Jiang L, et al
    AR loss in prostate cancer stroma mediated by NF-kappaB and p38-MAPK signaling disrupts stromal morphogen production.
    Oncogene. 2024 May 20. doi: 10.1038/s41388-024-03064.
    PubMed         Abstract available


    Oncology (Williston Park)

  19. JAMES B YU MD MHS FASTRO, Hong JC
    AI Use in Prostate Cancer: Potential Improvements in Treatments and Patient Care.
    Oncology (Williston Park). 2024;38:208-209.
    PubMed         Abstract available


    Pol J Radiol

  20. VIRARKAR MK, Gruschkus SK, Ravizzini GC, Vulasala SSR, et al
    Assessing the effectiveness of MRI, (18)F-fluciclovine PET, SUV(max), and PSA in detecting local recurrence of prostate cancer after prostatectomy.
    Pol J Radiol. 2024;89:e196-e203.
    PubMed         Abstract available


    Radiol Imaging Cancer

  21. HARMON SA, Turkbey B
    Integrating Whole-Slide Imaging and MRI Data for Outcome Prediction after Prostatectomy in Localized Prostate Cancer.
    Radiol Imaging Cancer. 2024;6:e240095.
    PubMed        


    Radiology

  22. PRIVE BM, Israel B, Janssen MJR, van der Leest MMG, et al
    Multiparametric MRI and (18)F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate Cancer.
    Radiology. 2024;311:e231879.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.